Clinical Trials Logo

Clinical Trial Summary

A phase I clinical trial of tolerability and pharmacokinetics of TQB2858 injection in subjects with advanced malignancy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05068921
Study type Interventional
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact Beihua Kong, Doctor
Phone 18560081888
Email kongbeihua@sdu.edu.cn
Status Recruiting
Phase Phase 1
Start date December 9, 2021
Completion date July 2023

See also
  Status Clinical Trial Phase
Completed NCT01088347 - Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer Phase 1/Phase 2
Completed NCT04590599 - A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy Phase 2
Terminated NCT02853604 - Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer Phase 3
Recruiting NCT04731038 - Combination Therapy for First Line Treatment of Advanced Cervical Cancer Phase 1
Recruiting NCT04508686 - Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1) Phase 1
Completed NCT02888717 - Molecular Biology Analysis for Para-aortic Nodes in the Ultra-staging of Advanced Cervical Cancers N/A